Kaifeng Lu

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Julio Rosenstock, Ronald Brazg, Paula J. Andryuk et al. · Clinical Therapeutics · 2006 · 516 citations

Medicine, Pharmacology, Pharmacotherapy +15

Ubrogepant for the Treatment of Migraine

David W. Dodick, Richard B. Lipton, Jessica Ailani et al. · New England Journal of Medicine · 2019 · 347 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine

Richard B. Lipton, David W. Dodick, Jessica Ailani et al. · JAMA · 2019 · 276 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?

G. Frank Liu, Kaifeng Lu, Robin Mogg et al. · Statistics in Medicine · 2009 · 247 citations

Public Health, Biostatistics, Causal Inference +14

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

Peter J. Goadsby, David W. Dodick, Jessica Ailani et al. · The Lancet Neurology · 2020 · 230 citations

Medicine, Neurology, Pharmacology +11